Pluristem Therapeutics PSTI shares are trading higher on Tuesday, after the company reported preliminary data from its coronavirus compassionate use program, treating seven patients with acute respiratory failure.
Pluristem Therapeutics is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.
Pluristem Therapeutics shares were trading up 37.20% at $4.61 on Tuesday at the time of publication. The stock has a 52-week high of $7.30 and a 52-week low of $2.82.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
